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Adams et al argue that we have not excluded two alternative explanations of our finding of 
extensive amyloid beta (Aβ) deposition in relatively young individuals who received extracts of 
human pituitary glands: that this pathology may be a consequence of either the underlying diagnosis 
for which the treatment was given or of the treatment with growth hormone itself irrespective of 
whether it was contaminated. As we made clear in our letter, our study was observational rather 
than an epidemiological or experimental one. While by its nature it cannot exclude these hypotheses 
(or other possible explanations for which there is no supportive evidence), we considered them 
unlikely. These patients received cadaveric pituitary-derived human growth hormone (c-hGH) for 
various reasons and those in our cohort who developed Aβ deposition were treated for 
pathogenetically unrelated conditions, or simply because of short stature of no obvious cause, 
making a common mechanism unlikely. Also we identified no publications that report a causal 
relationship between panhypopituitarism, short stature, or craniopharyngioma and Alzheimer’s 
disease or increased Aβ deposition.  
We also consider the proposal that growth hormone itself (acting through the GH-IGF axis) 
administered through adolescence is a possible trigger of Aβ deposition to be unlikely since IGF-1 
production is stimulated by growth hormone, and increased IGF levels are associated with increased 
Aβ clearance1,2 and decreased risk of Alzheimer’s disease3. Accordingly, the protracted treatment 
with growth hormone should have reduced accumulation of Aβ.  
Adams et al refer to our hypothesis (that A seeds in batches of c-hGH triggered A amyloidosis in 
recipients) as being untested. Clearly this cannot be experimentally tested in humans but there is a 
substantial body of experimental data in vitro and in vivo demonstrating -amyloid seeding, 
including as we cited in our letter that peripheral inoculation of laboratory mice with Alzheimer’s 
disease brain extracts leads to cerebral amyloid angiopathy. Investigating the role of seeded protein 
aggregation (often referred to as “prion-like” mechanisms) is one of the most active current areas of 
neurodegeneration research4. As we note, it will be important to examine archived batches of hGH 
for presence of A seeds by animal inoculation studies and this work is planned. 
To refer to our comparison with patients with other forms of prion disease unrelated to hGH 
treatment as futile is inappropriate. Were we to have found that patients with sporadic CJD or other 
forms of prion disease had a similar frequency and severity of A pathology at comparable ages, this 
would have argued strongly against our hypothesis, and indeed the two alternate hypotheses Adams 
et al suggest. An important question which we proposed in our letter was whether similar pathology 
suggestive of transmission of A seeds is seen in iatrogenic CJD caused by other medical procedures. 
The commonest other such cause is use of dura mater grafts. Demonstration of frequent 
Apathology in such patients, as has been reported in individual cases5,6 would support our 
hypothesis and dismiss those proposed by Adams and colleagues. 
However we agree with Adams et al that carefully controlled epidemiological studies are valuable 
and indeed we hoped that our study would stimulate such discussion and encourage precisely such 
work. With respect to comparing patients treated with hGH and synthetic hormone, this will be 
difficult as these necessarily represent different age cohorts.  
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